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Abstract Background: The pre-operative staging in oesophageal cancer is often challenging
and underestimation of the extent of the disease may lead to unnecessary surgery.
Aim: To audit the use and assess the value of fluorine-18 fluorodeoxyglucose positron emission
tomography (18F FDG-PET) as a staging tool for thoracic oesophageal and gastro-oesophageal
junction (GOJ) cancers in our oncological surgical practice.
Patients and methods: Over a 3 year period, between 2002 and 2004, 134 patients with tho-
racic oesophageal or GOJ cancer were referred to our unit for treatment. The standard preop-
erative staging investigation in all cases was CT (thorax, abdomen and pelvis). A preoperative
FDG-PET scan was further requested in 22 patients. The case notes of all the patients that
underwent a FDG-PET scan were reviewed and compared with the preoperative imaging, the
operative findings and the histopathology of the resected tumours.
Results: Eighteen men and 4 women with a median age of 65 (range 43e79) years were studied.
After FDG-PET, 13 out of 22 patients (59%) were deemed suitable for tumour resection. Twelve of
the13patientswerefit toundergo surgery.At laparotomy, 2of those (17%)were found inoperable
due towidespreaddisease. The sensitivity ofCTversus FDG-PET todetect infiltrated lymphnodes
was 29% (95%CI: 3e70) versus 71% (95%CI: 29e96) (PZ 0.0412),whereas both tests had67% spec-
ificity (95% CI: 9e99) in detecting lymph nodes. The sensitivity and the specificity of CT versus
FDG-PET to detect distant organ metastases (M1b) were 33% (95% CI: 4e77) and 88% (95% CI:
47e99) versus 50% (95% CI: 6e93) and 100% (95% CI: 69e100), respectively (P > 0.05). The
FDG-PET regarding the N and M status differed from the CT in 11 patients and led to modification
of the planned management in 5 of them.
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400 I.E. Katsoulis et al.Conclusions: FDG-PET ismore accurate thanCT in definingN andM status. It can result in a reduc-
tion of unnecessary surgery in a significant number of patients. The combined PETeCT scan as
a single imaging modality is expected to further improve diagnostic accuracy of FDG-PET.
ª 2007 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
The overall prognosis for thoracic oesophageal and gastro-
oesophageal junction (GOJ) cancers is poor mainly because
the majority of patients present with advanced disease.
Surgical resection offers hope of cure but less than 50% of
cases are suitable for surgery. It is only indicated for patients
in whom the tumour has not extended into adjacent
structures at the primary site (T1e3) and the disease has
not spread beyond the regional lymph nodes (N1). Other
patients, including those with distant nodal or organ metas-
tases (M1), are beyond cure and should be considered for
palliative treatment. Surgery, furthermore, is accompanied
by substantial morbidity and mortality.1 The key issue in the
assessment of patients with thoracic oesophageal and gas-
tro-oesophageal junction (GOJ) cancers is the appropriate
selection of those who could benefit from surgery.
Current preoperative staging is not entirely reliable and
unexpected local invasion of adjacent structures at the
primary site and distant metastases are still found during
surgery, rendering resection meaningless. Several studies
have shown that unnecessary explorative surgery, including
laparoscopy, is performed in between 10% and 60% of
patients.2e7
For over a decade, in the preoperative staging of
thoracic oesophageal and GOJ cancer, computed tomogra-
phy (CT) of the chest and abdomen has been used as the
main imaging modality to determine local resectability and
distant metastatic spread.8 CT, however, underestimates
stage of disease in more than 40% of cases, especially
with regards to T and N stage but also distant metastases
(M stage).9 In one study, CT missed 25% of M1 disease later
confirmed at surgery, mainly in the form of neck and ab-
dominal lymph nodal disease.10
Endoscopic ultrasonography (EUS) has increasingly been
included as part of the staging investigations for thoracic
oesophageal and GOJ cancer. It is, at present, the most
reliable method for identifying the depth of primary tumour
invasion (T staging). It is also considered reliable in
assessing regional and distant lymph node involvement,
particularly in combination with fine-needle aspiration
(FNA).11e13 However, this method is operator dependent
and is of limited value in patients with tight strictures at
the primary site.
Thoracoscopic and laparoscopic examination has been
shown to improve the accuracy of preoperative staging,
particularly in the evaluation of regional and coeliac lymph
nodes and they allow the detection of pleural and perito-
neal disease.14 However, they have not gained wide accep-
tance, as they are invasive investigations with their
attendant potential morbidity and also not withstanding
their considerable costs.
[18F]Fluorodeoxyglucose (18F-FDG) positron emission to-
mography (PET) has emerged as a useful metabolism-basedwhole body imaging tool for the staging of oesophageal
cancer. Fluorodeoxyglucose (FDG), an analogue of glucose,
is taken up by cells and trapped in the early stages of the
normal glycolytic pathway. The rationale behind the use
of FDG for cancer detection is based on the fact that in-
creased glycolytic activity is a hallmark of malignant
cells.15 More FDG is trapped in the cancer cells compared
with normal cells. Several studies have shown that FDG-
PET is more accurate for the detection of distant lymph
node involvement and organ metastases than conventional
imaging.16e24
The aim of the present study was to audit the use and
assess the value of FDG-PET as a staging tool for thoracic
oesophageal and GOJ cancers in our surgical oncology
practice.
Patients and methods
Over a 3 year period, between 2002 and 2004, 134 patients
with thoracic oesophageal or GOJ cancer were referred for
treatment to our unit.
The standard preoperative staging investigation in all
cases was CT of the thorax, abdomen and pelvis. CT
examinations were performed by multi-detector 16-slice
CT (Siemens Sensation 16, WI) using routine chest and
upper abdominal CT protocol. All patients were given
600e800 ml of diluted oral contrast (1:4 gastrografin/water)
45e60 min before the study and an additional 200 ml given
just before scanning. A total of 100 ml of non-ionic contrast
material (Optiray 300 mg of iodine per ml) was injected in-
travenously at a rate of 3 ml/s. Scanning was started at
35 s after injection for the thorax and after 65 s delay for
the upper abdomen. CT scanning parameters were as fol-
lows: acquisition slice thickness 50 mm; rotation time
0.5 s; pitch 1.5; reconstruction slice thickness 2.0 mm;
120 kV; 200 mA.
A preoperative FDG-PET scan was further requested in
22 patients due to either uncertain or suspicious findings on
CT scan that required further elucidation. PET was per-
formed using a CTI ECAT EXACT 47 PET scanner (Siemens
Medical Solutions, Bracknell UK). The scanner had an axial
and transaxial field of view (FOV) of 16.2 cm and 58.3 cm
respectively resulting in intrinsic axial and transaxial posi-
tion resolutions of 5 mm and 6 mm FWHM at the centre of
the FOV.
Patients were well hydrated before intravenous admin-
istration of FDG. Sixty minutes after injection of FDG
(6 MBq/kg body weight), emission and transmission data
was acquired from skull base to pubic symphysis. The
data was reconstructed using segmentation and an OSEM
(iterative) algorithm, with spatial resolution of 6 mm in
the finished images. Data was displayed in orthogonal
planes on a Sun workstation running CTI Software as
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servers (WLW, JC) interpreted the scans in consensus prior
to surgery. Endoscopic ultrasound scan (EUS) and laparos-
copy were not included routinely as part of the
investigations.
The case notes of all the patients who had FDG-PETwere
retrospectively reviewed. The CT scan and FDG-PET find-
ings were compared to the operative findings and to
histopathology. The accuracy of staging in the group of
inoperable patients was tested with biopsies of the nodal or
distant site metastases. The sensitivity, specificity, positive
predictive value (PPV) and negative predictive value (NPV)
for CT and FDG PET were calculated separately for the
detection of regional lymph nodes and distant metastases.
McNemar test was used for statistical comparisons and
a P < 0.05 was considered significant.
Results
The patient population comprised of 18 men and 4 women
with a median age of 65 years (range 43e79). Six of thetumours were squamous cell carcinomas (SCC) and 16
were adenocarcinomas (adenoca.). The location of the tu-
mour was in the upper thoracic oesophagus in 1 patient,
the middle thoracic oesophagus in 3, the lower thoracic
oesophagus in 9 and the GOJ in 9 patients (Table 1).
FDG-PET identified 21/22 primary sites. It failed to
diagnose tumour at the primary site in 1 patient with
a GOJ cancer, this lesion was also not diagnosed on CT but
subsequently confirmed by biopsy. The patient was treated
with radiotherapy and remains well.
After FDG-PET, 8 patients were deemed unsuitable for
surgery due to the stage of their disease. In another
patient, despite his carcinoma being stage I, radiotherapy
was offered as an alternative to surgery as he was not
mentally and physically fit for an oesophagectomy. The
remaining 13 patients (59%) were scheduled for surgery.
However, one of those patients with stage III lower thoracic
oesophageal carcinoma sustained a CVA during the
investigation period and surgery was cancelled.
Eventually 12 patients underwent surgery. In the 4
patients with stage I or IIA disease (T1-3N0M0) complete
resection was achieved either with oesophagectomy orTable 1 Preoperative staging, surgical management of the patients and histopathological staging of the resected tumours
Tumour
location
CT
staging
FDG-PET
staging
Surgical
management
Histopathological
staging
Lower 1/3 T1N0M1b (liver mets) T1 or T2N0M0 Transhiatal
oesophagectomy
T1N0M0
Upper 1/3 T4N0M0 T3 or T4N1M1a
(cervical nodes)
No surgery e
Lower 1/3 T3N0M1b (lung mets) T3N0M1b (lung mets) No surgery e
GOJ T3N0M0 T2 or T3N1M0 Total gastrectomy T4N1M0
GOJ T3N0M0 T2 or T3N0M0 Total gastrectomy T3N1M0
Lower 1/3 T3N1M0 T2 or T3N1M0 Oesophagogastrectomy T3N1M0
GOJ T3N0M0 T2 or T3N1M0 Oesophagogastrectomy T3N1M0
GOJ T3N0M0 T2N0M0 Oesophagogastrectomy T3N1M0
Middle 1/3 T3N1M0 T4N1M1b (parathracheal
and coeliac nodes)
No surgery e
GOJ T0N0M0 T0N0M0 No surgery e
Lower 1/3 T2N0M0 T1 or T2N0M0 Oesophagogastrectomy T2N0M0
Lower 1/3 T2N1M1b (lung mets) T3 or T4N1M1b (lung mets) No surgery e
Lower 1/3 T3N0M0 T2 or T3N1M0 ‘‘Open-close’’ Peritoneal mets.
Inoperable
GOJ T3N1M1a (coeliac nodes) T3N1M1b (bone mets) No surgery e
GOJ T3N1M1b (lung mets) T3N1M1a (coeliac nodes) ‘‘Open-close’’ Liver mets.
Inoperable
GOJ T3N1M1b (lung mets) T2 or T3N1M1a (coeliac
nodes)
No surgery e
Lower 1/3 T1 or T2N0M0 T1 or T2N0M0 No surgery (patient
unsuitable)
e
Middle 1/3 T3N0M0 T3N1M1b (cervical nodes) No surgery e
Lower 1/3 T2N1M1a (coeliac nodes) T2 or T3N1M1a (coeliac
nodes)
Oesophagogastrectomy T2N0M0
Lower 1/3 T3N1M0 T3N1M0 No surgery
(patient sustained CVA)
e
Middle 1/3 T3N0M0 T3N1M0 Oesophagogastrectomy T3N1M1a (coeliac
nodes)
GOJ T2N1M1a (coeliac nodes) T2 or T3N1M1a (coeliac
nodes)
Total gastrectomy T2N1M0
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tumour. In 4 out of 5 patients with IIB or III carcinomas
(T2 or T3N1M0) resection was performed whilst one patient
was found inoperable at laparotomy due to extensive
peritoneal involvement.
In 3 out of 5 patients with stage IVA disease (M1a),
a laparotomy was undertaken, as they were considered
suitable for operative treatment on the basis of the
location of their tumour and the distribution of the involved
lymph nodes. One of these patients, however, was found to
be inoperable at laparotomy due to liver metastases, not
diagnosed on FDG-PET. Complete resection was achieved in
the remaining 2 patients.
With regards to the N and M status, the FDG-PET differed
from the CT in 11 patients and led to modification of the
planned management in 5 of these. This occurred in 3 cases
that FDG-PET scan showed more extensive disease and
surgery was deemed inappropriate (paratracheal nodal
disease 1, cervical nodal disease 1, bone metastases 1)
and in two cases FDG-PET showed less extensive disease
and allowed surgery.
Nevertheless, preoperative staging with FDG-PET led to
unnecessary laparotomy in 2 patients by failing to show
liver metastases and peritoneal metastases, respectively.
In the group of the resected tumours, histopathological
staging showed that FDG-PET imaging of coeliac nodes was
falsely positive in 2 patients and falsely negative in 1.
The sensitivity of CT compared FDG-PET to detect
infiltrated regional and metastatic lymph nodes was 29%
(95% CI: 3e70) versus 71% (95% CI: 29e96) (PZ 0.0412);
both tests had a similar specificity, 67% (95% CI: 9e99).
The sensitivity and the specificity of CT compared FDG-
PET to detect distant organ metastases (M1b) were 33%
(95% CI: 4e77) and 88% (95% CI: 47e99) versus 50% (95% CI:
6e93) and 100% (95% CI: 69e100), respectively (P > 0.05).
The PPV and the NPV of FDG-PET were higher than those
of CT for both lymph nodes and distant organ metastases
detection (Table 2).
Discussion
Several studies have shown that FDG-PET is more accurate
for the detection of lymph node involvement and organ
metastases than conventional imaging (sensitivity 45e55%
and specificity 90e100% compared with sensitivity 88e96%
and specificity 93e95%, respectively).16e24 The present
series provides further evidence that FDG-PET is moreaccurate than CT for detecting infiltrated lymph nodes
and visceral metastases.
There are a number of studies that have demonstrated
that the additional information provided by FDG PET will
alter treatment plan. These however have been based on
patients and surgical practice on continental Europe and
the USA. Transposition of such data to the UK has its
limitations. This is the first study that has shown the utility
of FDG-PET in thoracic oesophageal and gastro-oesophageal
cancer in a UK setting.
FDG-PET does not evaluate the local resectability of the
tumour. PET reflects functional activity of the tissues but
does not provide anatomical detail; this was borne out
in our study where CT offered more accurate T staging
(Table 1).
Our study demonstrates that FDG-PET is superior to CT
for detecting regional nodal disease. This however is of
limited use as the presence or absence of regional nodal
disease does not directly influence operability.
The main strength of FDG-PET is its superiority for
detecting distant metastases compared with conventional
imaging. In our study FDG-PET showed disease that pre-
cluded surgery in 3 patients (1 with paratracheal and
cervical nodal disease, 1 with cervical nodal disease, 1
with bone metastases) and down staged disease in a 2
further patients that allowed for a surgical option. Histo-
logical proof of distant spread was confirmed in those
patients where staging was altered by FDG-PET.
Thus, FDG-PET provided additional information overall
in 5/22 (23%) patients (down staged disease 2, upstaged
disease 3), which directly influenced the plan of treatment.
Nevertheless, FDG-PET failed to identify 2 patients with
widespread disease. We can reasonably assume that in our
two cases with peritoneal and liver spread, a laparotomy
could have been avoided if laparoscopy was part of the
preoperative staging. However, laparoscopy has not found its
place yet as a routine preoperative diagnostic tool in our unit.
It is obvious that each test has its limitations and
combination of the CT scan (which offers anatomical
information) with PET (which reflects functional activity)
in an integrated PET/CT modality is expected to achieve
even more accurate detection of the metastatic sites. It
reduces inaccurate results by more accurately distinguish-
ing physiological from pathological uptake.25
In conclusion, FDG-PETas part of preoperative staging for
oesophageal cancer is more sensitive than CT in defining N
and M status. The development of PET radiotracers
with improved tumour specificity and the use of combinedTable 2 The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of each test were
calculated separately for the detection of lymph nodes and distant metastases
Lymph nodes Distant metastases
CT FDG-PET CT FDG-PET
Sensitivity (%) 29 (3e70) 71 (29e96) 33 (4e77) 50 (6e93)
Specificity (%) 67 (9e99) 67 (9e99) 88 (47e99) 100 (69e100)
PPV (%) 67 (9e99) 83 (35e99) 67 (9e99) 100 (15e100)
NPV (%) 29 (3e70) 50 (6e93) 64 (30e89) 83 (51e97)
95% confidence interval.
18F-FDG-PET in preoperative staging of oesophageal cancer 403PET/CT should further enhance the utility of PET for this
disease and will hopefully translate into better treatment
planning.
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